Interestingly, the co-existence of KRAS mutation and PIK3CA mutation has also been found in other tumor types such as ovarian carcinoma [14], suggesting that such co-occurrence might provide a selective advantage to carcinoma cells from various origins. This evidence concerns the gene KRAS and neoplasm.